Catalyst Clinical Research has acquired Aptus Clinical for expediting expansion to Europe, widening client services, and improving patient impact.

The acquisition is aimed at expanding the companies geographically and boosting patient access to new treatments. 

With the acquisition, Catalyst and Aptus will combine to become a multi-region clinical research organisation (CRO) with an expedited growth trajectory in the US as well as Europe.

The takeover will merge geographic strengths, complementary service offerings and treatment capabilities of the entities to progress research for enhanced patient outcomes.

Offerings of Catalyst will now include wide-ranging clinical consulting services, as it inherits Aptus’ relationship with the Experimental Cancer Medicine Centre (ECMC) network to facilitate clinical trial set-up and design input. 

The combined business will operate as Catalyst Oncology and continue to offer a portfolio of over 100 active oncology studies through a network comprising 500 investigator sites. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Further studies outside of the Oncology therapeutic area will be carried out under the Catalyst Flex solution and operating models. 

The merged company will have more than 800 staff members.

Furthermore, Catalyst plans to harness strategic site relationships of Aptus by incorporating them into its site network in North America and Europe. 

Catalyst’s active portfolio, which is at forefront of new cancer therapy trends, serves over 5,300 patients with cancer and will increase by approximately 600 patients in line with the Aptus takeover.

Established by three former clinical development specialists from AstraZeneca in 2014, Aptus is a specialist CRO that provides adaptable clinical research solutions in rare diseases and oncology, cell and gene therapies. 

Catalyst Clinical Research CEO Nick Dyer said: “We are thrilled to be working with Aptus Clinical to expand our reach in the European market, serving clients around the globe to help develop innovative new therapies, improve patient outcomes and enhance our company’s long-term impact. 

“Our complementary service offerings and therapeutic area alignment will improve outcomes for all our clients.”